Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism (SPACE)

July 21, 2020 updated by: Yongjun Wang, Beijing Tiantan Hospital

A Random, Double-blind, Parallel, Placebo-controlled, Multi-center Study of Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism

This is a randomized, double blind, placebo-controlled, parallel, multicenter research in order to evaluate the effect of Shuxuetong injection in prevention of symptomatic or asymptomatic new cerebral infarction within 10 days.

Subgroup study:Evaluate the role of advanced diagnostic technique in identifying potential causes of Embolic Stroke of Undetermined Source (ESUS).

Study Overview

Status

Completed

Conditions

Detailed Description

Shuxuetong injection or Placebo injection for 10days. About 2416 patients randomized at 80 centers all over China with 20 subgroup study centers.

Face to face interview at baseline, 10 days, and 90 days.

Study Type

Interventional

Enrollment (Actual)

2416

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Anhui
      • Wuhu, Anhui, China
        • Wuhu No.1 People's Hospital
    • Beijing
      • Beijing, Beijing, China, 100050
        • Beijing Tian Tan Hospital, Capital Medical University
      • Beijing, Beijing, China
        • ANSTEEL Group Hospital
      • Beijing, Beijing, China
        • Beiujing Fengtai Youanmen Hospital
      • Beijing, Beijing, China
        • The First Hospital of Fangshan District
    • Chongqing
      • Chongqing, Chongqing, China
        • Yongchuan hospital of Traditional Chinese Medicine
    • Guangzhou
      • Dongguan, Guangzhou, China
        • Houjie Hospital
    • Hebei
      • Cangzhou, Hebei, China
        • Cangzhou Peoole's Hospital
      • Cangzhou, Hebei, China
        • People's Hospital of Hejian
      • Chengde, Hebei, China
        • Kuancheng County Hospital
      • Handan, Hebei, China
        • Traditional Chinese Medicine Hospital of Qiu County
      • Hengshui, Hebei, China
        • Hengshui Fourth Hospital
      • Hengshui, Hebei, China
        • Jizhou District Hospital of Hengshui
      • Shijiazhuang, Hebei, China
        • The Second Hospital of Hebei Medical University
      • Shijiazhuang, Hebei, China
        • Shijiazhuang Pingan Hospital Affiliated to Hebei Medical University
    • Heilongjiang
      • Jiamusi, Heilongjiang, China
        • The Second Affiliated Hospital of Jiamusi University
      • Mudanjiang, Heilongjiang, China
        • Heilongjiang Province Agricultural Reclamation Mudanjiang Authority Central Hospital
    • Henan
      • Handan, Henan, China
        • Handan Municipal Center Hospital
      • Hengyang, Henan, China
        • The First Affiliated Hospital of University of South China
      • Zhengzhou, Henan, China
        • People's Hospital of Zhongmu
      • Zhengzhou, Henan, China
        • Zhengzhou Yihe Hospital Affiliated to Henan University
    • Hubei
      • Jingmen, Hubei, China
        • Jingmen City Hospital of Traditional Chinese Medicine
      • Wuhan, Hubei, China
        • Wuhan NO.1 Hospital,Wuhan Hospital Of Traditional Chinese And Western Medicine
    • Jiangsu
      • Nanjing, Jiangsu, China
        • Jiangsu Province Hospital of TCM
      • Nantong, Jiangsu, China
        • Nantong 3rd People's Hospital
      • Suzhou, Jiangsu, China
        • Zhangjiagang First People's Hospital
      • Suzhou, Jiangsu, China
        • Zhangjiagang Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Chinese Medicine
      • Xuzhou, Jiangsu, China
        • The Affiliated Hospital of Xuzhou Medical College
    • Jiangxi
      • Nanchang, Jiangxi, China
        • Jiangxi Provincial People's Hospital
    • Jilin
      • Changchun, Jilin, China
        • The First Hospital of Jilin University-the Eastern Division
    • Liaoning
      • Huludao, Liaoning, China
        • The Second People's Hospital of Huludao
      • Jinzhou, Liaoning, China
        • Jinzhou Medical University
    • Neimenggu
      • Baotou, Neimenggu, China
        • The First Affiliated Hospital of Baotou Medical College
      • Bayan Nur, Neimenggu, China
        • Wu Yuan People's Hospital
      • Chifeng, Neimenggu, China
        • Affiliated Hospital of Chifeng University
    • Shandong
      • Binzhou, Shandong, China
        • Huimin People's Hospital
      • Dezhou, Shandong, China
        • Ningjin County People's Hospital
      • Jinan, Shandong, China
        • Shandong Provincial Western Hospital
      • Penglai, Shandong, China
        • People's Hospital of Penglai
      • Qingdao, Shandong, China
        • The Affiliated Hospital of Qingdao University
      • Qingdao, Shandong, China
        • People's Hospital of Qingdao West Coast New Area
      • Qingdao, Shandong, China
        • Qingdao Haci medical group hospital
    • Shanxi
      • Taiyuan, Shanxi, China
        • First Hospital of Shanxi Medical University
    • Shenzhen
      • Shenzhen, Shenzhen, China
        • The second people's Hospital of Shenzhen
    • Zhejiang
      • Dongyang, Zhejiang, China
        • Dongyang People's Hopital
      • Lishui, Zhejiang, China
        • Lishui People's Hospital
      • Taizhou, Zhejiang, China
        • No.1 People's Hospital of Taizhou
      • Wenzhou, Zhejiang, China
        • Ruian People's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria

  1. More than or equal to 18 years old and less than 80 years old;
  2. Acute ischemic stroke, brain magnetic resonance imaging showed non lacunar infarction (subcortical infarction less than or equal to 1.5 cm);
  3. Onset within 72 hours;
  4. Patients or their family members are willing to sign the informed consent.

Exclusion criteria

  1. Intracranial hemorrhage: cerebral hemorrhage, subarachnoid hemorrhage, etc.;
  2. Transient ischemic attack;
  3. Lacunar infarction;
  4. History of acute stroke within 6 months;
  5. Clear diagnosis of other causes of ischemic stroke (arterial dissection, arteritis, vasospasm, etc.);
  6. The acute infarcts lesion more than one-half lobe in size;
  7. Preceding modified Rankin Scale (mRS) score ≥ 2;
  8. Cumulative usage of traditional Chinese medicine which activating blood circulation more than 3 times after onset, including but not limited to: Danhong, Xueshuantong, Xuesaitong, Ginkgo biloba, sodium ozagrel, Salvia miltiorrhiza, ligustrazine, Erigeron breviscapus, etc;
  9. Chronic liver disease, liver and kidney dysfunction, lifted alanine aminotransferase (>3 times the ULN), lifted serum creatinine (>2 times the ULN);
  10. History of coagulopathy, systemic bleeding, thrombocytopenia or neutropenia;
  11. Blood pressure >90/60 mmHg or ≤220/120 mmHg after treatment;
  12. Serious heart or lung disease, in the judgment of clinical study staff, would not suitable to participant in the trial;
  13. Patients with atrial fibrillation who were scheduled or likely to receive anticoagulant therapy with unfractionated heparin or low molecular weight heparin within 2 weeks after randomization
  14. A medical condition likely to limit survival to less than three months or any other condition judged by the clinic team to likely limit the adherence to study procedures;
  15. Known allergies for ingredients of the drug, allergy history for food or drug;
  16. Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control;
  17. Participation in another clinical trial within 30 days;
  18. Unable to understand and/or comply with the study procedures and/or follow-up studies due to mental illness, cognitive or emotional disorders.

Subgroup Exclusion Criteria

  1. History of atrial fibrillation
  2. Atrial fibrillation in 12-lead electrocardiogram (ECG);
  3. Heart rate monitoring (dynamic electrocardiogram telemetry) up to 20 hours or more detected atrial fibrillation for 6 minutes or more;
  4. Intracardiac thrombosis in thoracic or esophageal echocardiography;
  5. Occlusion or proximal vessel infarction for more than 50%.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Shuxuetong Injection
Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;
intravenous drip
Other Names:
  • Shuxuetong
PLACEBO_COMPARATOR: Placebo Injection
Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;
intravenous drip
Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Symptomatic or Asymptomatic New Cerebral Infarction
Time Frame: 10 days
Those patients who are still alive at 10 days after randomization will be contacted to set up a follow-up clinical visit. Information of recurrent symptomatic cerebral infarction will be collected and MRI examination will be performed to detect asymptomatic new cerebral infarction.
10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Symptomatic Cerebral Infarction
Time Frame: 10 days
Those patients who are still alive at 10 days after randomization will be contacted to set up a follow-up clinical visit. Information of recurrent symptomatic cerebral infarction will be collected.
10 days
Asymptomatic Cerebral Infarction
Time Frame: 10 days
Those patients who are still alive at 10 days after randomization will be contacted to set up a follow-up clinical visit. MRI examination including diffusion weighted imaging (DWI) sequence will be performed.
10 days
Cerebral Infarction Volume Expansion
Time Frame: 10 days
Those patients who are still alive at hospital discharge will be contacted to set up a follow-up clinical visit. MRI examination will be performed.
10 days
NIHSS Score Increase
Time Frame: 10 days
Those patients who are still alive at hospital discharge will be contacted to set up a follow-up clinical visit. Neurological and functional assessments including NIHSS will be performed.
10 days
Recurrent Symptomatic Stroke(Cerebral infarction, cerebral hemorrhage)
Time Frame: 90 days
Those patients who are still alive at 90days after onset will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent symptomatic stroke will be collected.
90 days
Recurrent Symptomatic Ischemic Stroke
Time Frame: 90 days
Those patients who are still alive at 90days after onset will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent symptomatic ischmemic stroke will be collected.
90 days
Combined Vascular Events
Time Frame: 90 days
Combined Vascular Events was defined as a combination of symptomatic stroke, myocardial infarction and vascular death.
90 days
Disability or Death
Time Frame: 90 days
Disability or Death was defined as a score of 3 to 6 on the modified Rankin Scale at 90days after onset.
90 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detected an Atrial Fibrillation Persistent ≥ 30s
Time Frame: 90 days
Pre-specified Outcomes for Substudy of 'Etiology Study in Patients with ESUS'
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Wang yongjun, MD, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 12, 2017

Primary Completion (ACTUAL)

March 30, 2019

Study Completion (ACTUAL)

June 21, 2019

Study Registration Dates

First Submitted

March 9, 2017

First Submitted That Met QC Criteria

March 18, 2017

First Posted (ACTUAL)

March 24, 2017

Study Record Updates

Last Update Posted (ACTUAL)

July 22, 2020

Last Update Submitted That Met QC Criteria

July 21, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Embolic Stroke

Clinical Trials on Shuxuetong Injection

Subscribe